Literature DB >> 1375199

Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A.

S M Frey1, T D Wilkins.   

Abstract

The toxin A gene of Clostridium difficile contains a 2.5-kb region encoding a series of contiguous repeating units located at the COOH terminus of the molecule. We previously showed that the monoclonal antibody (MAb) PCG-4, which neutralizes the enterotoxic activity of toxin A, binds to epitopes located within these repeating units. In the present study, we subcloned a series of fragments from this portion of the gene. The recombinant peptides expressed from the gene fragments were examined for reactivity with MAb PCG-4 to identify the epitopes involved in binding. Our results showed that MAb PCG-4 recognizes epitopes in amino acid residues 2097 through 2141 and amino acid residues 2355 through 2398.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375199      PMCID: PMC257186          DOI: 10.1128/iai.60.6.2488-2492.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Molecular characterization of the Clostridium difficile toxin A gene.

Authors:  C H Dove; S Z Wang; S B Price; C J Phelps; D M Lyerly; T D Wilkins; J L Johnson
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 3.  Empirical predictions of protein conformation.

Authors:  P Y Chou; G D Fasman
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

4.  A rapid alkaline extraction method for the isolation of plasmid DNA.

Authors:  H C Birnboim
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Identification of Clostridium difficile as a cause of pseudomembranous colitis.

Authors:  R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon
Journal:  Br Med J       Date:  1978-03-18

6.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.

Authors:  J G Bartlett; T W Chang; M Gurwith; S L Gorbach; A B Onderdonk
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

7.  Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters.

Authors:  J M Libby; B S Jortner; T D Wilkins
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

8.  Comparison of two toxins produced by Clostridium difficile.

Authors:  N S Taylor; G M Thorne; J G Bartlett
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Clostridium difficile and the aetiology of pseudomembranous colitis.

Authors:  H E Larson; A B Price; P Honour; S P Borriello
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

View more
  29 in total

1.  Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A.

Authors:  C Pothoulakis; R J Gilbert; C Cladaras; I Castagliuolo; G Semenza; Y Hitti; J S Montcrief; J Linevsky; C P Kelly; S Nikulasson; H P Desai; T D Wilkins; J T LaMont
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 2.  Clostridium difficile toxins: mechanism of action and role in disease.

Authors:  Daniel E Voth; Jimmy D Ballard
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.

Authors:  Scott M Baliban; Amanda Michael; Berje Shammassian; Shikata Mudakha; Amir S Khan; Simon Cocklin; Isaac Zentner; Brian P Latimer; Laurent Bouillaut; Meredith Hunter; Preston Marx; Niranjan Y Sardesai; Seth L Welles; Jeffrey M Jacobson; David B Weiner; Michele A Kutzler
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

4.  Positive regulation of Clostridium difficile toxins.

Authors:  J S Moncrief; L A Barroso; T D Wilkins
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

5.  Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells.

Authors:  E Chaves-Olarte; M Weidmann; C Eichel-Streiber; M Thelestam
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

6.  Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity.

Authors:  Michelle E LaFrance; Melissa A Farrow; Ramyavardhanee Chandrasekaran; Jinsong Sheng; Donald H Rubin; D Borden Lacy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

Review 7.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

8.  Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.

Authors:  E T Ryan; J R Butterton; R N Smith; P A Carroll; T I Crean; S B Calderwood
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

9.  Crystal structure of Clostridium difficile toxin A.

Authors:  Nicole M Chumbler; Stacey A Rutherford; Zhifen Zhang; Melissa A Farrow; John P Lisher; Erik Farquhar; David P Giedroc; Benjamin W Spiller; Roman A Melnyk; D Borden Lacy
Journal:  Nat Microbiol       Date:  2016-01-11       Impact factor: 17.745

10.  Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A.

Authors:  Tim Du; Michelle J Alfa
Journal:  Can J Infect Dis       Date:  2004-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.